Cardinal Health is advancing molecular imaging in clinical trials

Cardinal Health Corporation and the University of Washington, today announced the establishment of innovative public and private sector partnerships to promote molecular imaging in clinical research and trials.

Molecular Imaging is biotechnology, one of the most promising area of development, molecular imaging by dedicated radioactive substances or Positron Emission Tomography (PET) Imaging agents ", injection into the human body to detect and track and cardiac diseases, nervous system diseases and various forms of cancer-related lesions cell function.

Using state-of-the-art imaging scanners can observe that the imaging agent for doctors for noninvasive diagnostic, monitoring and early onset of most treatments.

Through this cooperation, Department of Radiology, University of Washington will put their molecular Tracker lab part of relocation to Cardinal Health company located in the downtown area of Seattle PET manufacturing plants.

In the relocation of Washington University Lab, including a John Grierson, leading the development of PET drugs F-18 fluorothymidine (FLT, fluorine thymidine) laboratory, PET pharmacy F-18 fluorothymidine now by Cardinal Health company sales in the United States, and is used in a series of clinical trials.

University of Washington, Department of Radiology will have the opportunity to use the Cardinal Health company of the cyclotron, radiopharmaceutical products and research support services to assist the effective operation and development of the factory.

By moving to the same location, the two organizations will Washington University an internationally accredited pet studies and research and development experience and Cardinal Health companies comply with FDA standards for PET Imaging agent for the production and sales experience to accelerate new molecular imaging agents for research, development and commercialization of promotion.

Washington University is the United States one of the leading research institutions, their resulting from the United States national institutes of health research funding than any other United States public universities.

Cardinal Health company of the nuclear medicine services business holds the largest distribution network of radioactive substances. The company also strategically established a national network of the cyclotron, making the most of radioactive drugs pharmacies can take the form of unit dose and the preparation of a high energy mix PET Imaging agent. Cardinal Health has a huge number of "support to PET" pharmacies, its wide range of nuclear medicine size, comprehensive logistics and distribution capabilities to enable it to support or non-authorised Imaging agents in clinical trials play a key role.

Cardinal Health company started expansion of its plant in Seattle to accommodate Washington University's new radiochemistry laboratory, researchers at the University of Washington, and Cardinal Health company staff and technicians work together.

The refurbishment and extension of the factory is expected to be completed by early 2011.